Barclays lowered the firm’s price target on Bruker (BRKR) to $45 from $50 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker unveils NMR products, workflow solutions at ENC 2026
- Bruker Announces Planned Transition of BioSpin Group President
- Bruker invests in photothermal AFM-IR to advance semiconductor research
- Bruker Expands Board, Appoints Thierry Bernard as Director
- Bruker appoints Bernard to its Board of Directors